KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeMD (LFMD) Interest Expenses (2016 - 2025)

Historic Interest Expenses for LifeMD (LFMD) over the last 14 years, with Q3 2025 value amounting to $262456.0.

  • LifeMD's Interest Expenses fell 5301.51% to $262456.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 112.29%. This contributed to the annual value of $2.2 million for FY2024, which is 1597.36% down from last year.
  • According to the latest figures from Q3 2025, LifeMD's Interest Expenses is $262456.0, which was down 5301.51% from $663027.0 recorded in Q2 2025.
  • LifeMD's Interest Expenses' 5-year high stood at $1.8 million during Q3 2021, with a 5-year trough of $132235.0 in Q3 2022.
  • In the last 5 years, LifeMD's Interest Expenses had a median value of $558597.0 in 2024 and averaged $559253.8.
  • Its Interest Expenses has fluctuated over the past 5 years, first plummeted by 9275.34% in 2022, then soared by 65294.93% in 2023.
  • Quarter analysis of 5 years shows LifeMD's Interest Expenses stood at $153566.0 in 2021, then surged by 449.3% to $843541.0 in 2022, then decreased by 26.18% to $622685.0 in 2023, then decreased by 1.38% to $614074.0 in 2024, then crashed by 57.26% to $262456.0 in 2025.
  • Its Interest Expenses was $262456.0 in Q3 2025, compared to $663027.0 in Q2 2025 and $626275.0 in Q1 2025.